Jim Cramer's Stop Trading: Jazz Pharmaceuticals Faces Music

NEW YORK (TheStreet) -- Jazz Pharmaceuticals (JAZZ) "did not hit the numbers, so the stock is down," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. 

The company missed analysts' estimates for its top- and bottom-line results. Cramer said he's highlighting Jazz Pharmaceuticals because of how poorly biotechnology stocks have performed over the past two months.

Turning to WhiteWave Foods (WWAV), "I thought that quarter was amazing," he said of the company's top and bottom line earnings beat. 

He added that Hain Celestial Group (HAIN) is also doing very well, and its CEO Irwin Simon is "too clever" for the short-sellers.

- - Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

7 Takeaways From Google's $550-Million Investment in Alibaba Rival JD.com

7 Takeaways From Google's $550-Million Investment in Alibaba Rival JD.com

It's Just Not Smart For Investors to Ignore the Threat of a Trade War

It's Just Not Smart For Investors to Ignore the Threat of a Trade War

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

Flashback Friday in Politics: Trade Wars, Manafort, Immigration Dominate Minds

Flashback Friday in Politics: Trade Wars, Manafort, Immigration Dominate Minds

Microsoft and Sony's Rumored Game Console Plans Bode Well for AMD

Microsoft and Sony's Rumored Game Console Plans Bode Well for AMD